DavidS.GoldfarbMD

Nephrology • New York, NY

Director, Kidney Stone Prevention Program and Professor of Medicine & Physiology, NYU Grossman School of Medicine

Join to view full profile

Dr. Goldfarb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldfarb's full profile

Already have an account?

Office
222 E 41st St
New York, NY 10017
Phone+1 212-263-5851

Fax+1 212-434-6370

Summary

Dr. David Goldfarb is a nephrologist in New York, NY and is affiliated with VA NY Harbor Healthcare System, Manhattan Campus and NYU Langone Hospitals. He received his medical degree from Yale University School of Medicine and has been in practice 36 years. He is experienced in cystinuria, medullary sponge kidney, nephrolithiasis, Dent disease, CKD, ESKD, COVID-19 and gout.

Education & Training

NYU Grossman School of MedicineFellowship, Nephrology, 1985 - 1987
NYU Grossman School of Medicine (Veterans)Residency, Internal Medicine, 1981 - 1985
Yale School of MedicineClass of 1981

Certifications & Licensure

NY State Medical License 1983 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Fellow (FASN) American Society of Nephrology
Fellow, NKF National Kidney Foundation, 2014
Super Doctor SuperDoctors.com

Clinical Trials

The Effects of Sports Drinks on Urinary Lithogenicity Start of enrollment: 2006 Mar 01
Completed
Not Applicable
Rare Kidney Stone Consortium Patient Registry Start of enrollment: 2003 Jul 01
Recruiting
Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers Start of enrollment: 2009 Nov 01
Completed
Not Applicable
Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter Formigenes Start of enrollment: 2003 Jan 01
Completed
Effect of Diet Orange Soda on Urinary Lithogenicity Start of enrollment: 2009 Nov 01
Completed
Not Applicable
Blood Volume Analysis and Related Outcomes in Hemodialysis Start of enrollment: 2012 Jan 01
Completed
Cystine Capacity Clinical Study (CysCap) Start of enrollment: 2012 Sep 01
Completed
Health-related Quality of Life in Rare Kidney Stone Start of enrollment: 2013 Aug 01
Completed
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria Start of enrollment: 2012 Jun 01
Completed
Phase 4
Prospective Research Rare Kidney Stones (ProRKS) Start of enrollment: 2016 May 01
Recruiting
Effect of Hydroxycitrate on Urine Chemistry Start of enrollment: 2018 Oct 04
Completed
Not Applicable
Registry of Thiola EC Therapy Start of enrollment: 2021 Mar 02
Completed
Roles: Principal Investigator, Contact
Gut Kidney Axis in Enteric Hyperoxaluria Start of enrollment: 2022 Nov 10
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

Other

Opioid Overuse or NSAID Underuse? A Response to the Pain Guide
David Goldfarb, MD, American Journal of Kidney Diseases
https://www.doximity.com/articles/f5536f97-56ab-4efb-8c6e-3feb55264fa5
UpToDate, Wolters Kluwer Health - 2012-05-15

Press Mentions

SGLT2 Inhibitors Might Lower Stone Risk Better Than Other Type 2 Diabetes DrugsNovember 15th, 2024
All About Type 1.5 Diabetes, Lance Bass DiseaseJuly 30th, 2024
Removal of Small, Asymptomatic Kidney Stones Cuts Relapse RiskAugust 12th, 2022
Join now to see all